Shares of Indivior PLC (LON:INDV – Get Free Report) dropped 15.7% on Thursday . The company traded as low as GBX 548.71 ($6.90) and last traded at GBX 732 ($9.21). Approximately 1,888,371 shares were traded during trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.92).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 1,800 ($22.65) target price on shares of Indivior in a report on Tuesday, December 17th.
Get Our Latest Stock Report on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Most Volatile Stocks, What Investors Need to Know
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Investing In Automotive Stocks
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Pros And Cons Of Monthly Dividend Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.